Molecular targeted therapy of <i>BRAF</i> -mutant colorectal cancer
Michel Ducreux(Université Paris-Saclay), Maximiliano Gelli(Université Paris-Saclay), David Malka(Inserm), Ali N. Chamseddine(Institut Gustave Roussy), Valérie Boige(Inserm), Peggy Dartigues(Institut Gustave Roussy), Antoine Hollebecque(Institut Gustave Roussy), Emmanuelle Samallin(Institut de Recherche en Cancérologie de Montpellier), Pierre Laurent‐Puig(Inserm), Cristina Smolenschi(Institut Gustave Roussy)
Cited by 102
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k